Related Experiment Video
Updated: May 31, 2026
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia
Kate A Alford1, Katarina Reinhardt, Catherine Garnett
1Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Insights
Children with Down syndrome have a high risk of myeloid leukemia (ML-DS). GATA1 mutations are common in both transient myeloproliferative disorder (TMD) and ML-DS, but mutation type does not predict progression.
Area of Science:
- Hematology
- Genetics
- Pediatrics
Background:
- Children with Down syndrome (DS) exhibit a significantly elevated risk of myeloid leukemia (ML-DS), occurring up to 150 times more frequently than in the general population.
- A substantial percentage of newborns with DS (4%-5%) develop transient myeloproliferative disorder (TMD), a condition sharing similarities with ML-DS.
Purpose of the Study:
- To investigate the prevalence and spectrum of GATA1 mutations in transient myeloproliferative disorder (TMD) and myeloid leukemia in Down syndrome (ML-DS).
- To determine if GATA1 mutation type can serve as a prognostic marker for the development of ML-DS from TMD.
Main Methods:
- Utilized simple techniques to detect GATA1 mutations.
- Analyzed a large cohort of patients with TMD (n=134) and ML-DS (n=103).
Main Results:
- GATA1 mutations were detected in 88% of TMD cases and 85% of ML-DS cases.
- No significant differences were observed in the mutational spectrum of GATA1 between TMD and ML-DS.
Conclusions:
- The presence of GATA1 mutations is a common feature in both TMD and ML-DS.
- The specific type of GATA1 mutation is not a reliable prognostic indicator for predicting which patients with TMD will progress to ML-DS.
Abstract:
Children with Down syndrome (DS) up to the age of 4 years are at a 150-fold excess risk of developing myeloid leukemia (ML-DS). Approximately 4%-5% of newborns with DS develop transient myeloproliferative disorder (TMD). Blast cell structure and immunophenotype are similar in TMD and ML-DS. A mutation in the hematopoietic transcription factor GATA1 is present in almost all cases. Here, we show that simple techniques detect GATA1 mutations in the largest series of TMD (n = 134; 88%) and ML-DS (n = 103; 85%) cases tested. Furthermore, no significant difference in the mutational spectrum between the 2 disorders was seen. Thus, the type of GATA1 sequence mutation is not a reliable tool and is not prognostic of which patients with TMD are probable to develop ML-DS.
Related Concept Videos
01:17Karyotyping
01:49Meiosis I